Effects Of Thalidomide and Stem Cell Factor On Fetal Hemoglobin Synthesis
Effects Of Thalidomide and Stem Cell Factor On Fetal Hemoglobin Synthesis
批准号:
7969153
负责人:
GRIFFIN RODGERS
金额:
$34.29万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AdultApoptosisAttenuatedButyratesCD34 geneCell CountCell ProliferationCellsClinicalClinical TrialsDataDecitabineDiseaseDown-RegulationDysmyelopoietic SyndromesErythroblastsErythroidErythropoiesisFetal HemoglobinG1 PhaseGene ExpressionGenerationsGenesGlobinGoalsGrowthHemoglobinHereditary DiseaseHistonesHumanMAP Kinase GeneMAPK Signaling Pathway PathwayMAPK11 geneMAPK14 geneMediatingMolecularNuclear TranslocationPathway interactionsPatientsPhosphorylationPlayProtein Kinase C AlphaProtein Serine/Threonine PhosphataseRNA Polymerase IIRas/RafReactive Oxygen SpeciesRegulationResearchRoleSickle Cell AnemiaSignal PathwaySignal TransductionStem Cell FactorStem cellsStreamStressSymptomsThalidomideTherapeuticTherapeutic EffectThioredoxinTimeTranscription CoactivatorTrichostatin AUp-RegulationapoAI regulatory protein-1basebeta Globinbeta Thalassemiacell growthcell typedosagedrug mechanismfetal globingamma Globingene inductionhydroxyureainhibitor/antagonistinsightpreventpromotertherapeutic targettranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Thalidomide has been shown to be effective in some patients with myelodysplastic syndromes (MDS), increasing both the total hemoglobin and in the proportion of the fetal hemoglobin in some patients in clinical trials. Also, it has been demonstrated that thalidomide increases the intracellular reactive oxygen species (ROS) in embryoid bodies. The mechanisms of thalidomides therapeutic effect are still being defined. We hypothesize that thalidomide induces the gamma-globin gene expression in adult erythropoiesis, and that this induction may be mediated by increased ROS formation. To investigate this hypothesis, we assessed the effect of increasing dosages of thalidomide (0.01uM to 100uM) on cell growth, globin gene expression and ROS generation using cultured primary human CD34+ progenitor cells. The effects of varying concentrations of thalidomide on the cultured CD34+ cells, demonstrate a significant increase in cell number at maximum thalidomide concentration of 100uM. Real time quantitative PCR analysis of gamma- and & beta-globin gene expression demonstrated that thalidomide significantly induces gamma-globin induced by SCF is through a PKC-alpha-dependent Ras/Raf/Erk1/2 signaling pathway involving activation of the transcription factor NF-Ya and inhibition of the repressor Coup-TFII. Specific inhibition of PKC-alpha with Go6976 blocked both activation of Erk1/2 and p38 MAPK induced by SCF, and abrogated the SCF increased gamma-globin gene expression. Activation of Erk1/2 plays a critical role in SCF modulated down-stream transcriptional regulators, involving regulation of gamma-globin gene induction. SCF induced nuclear translocation of NF-Ya is required to activate Erk1/2 increased phosphorylation of endogenous Nrf2, which involves up-regulation of thioredoxin, and down-regulation of Coup-TFII. Inhibition of either PKC-alpha or Erk1/2 prevented SCF induced recruitment of NF-Ya, RNA polymerase II and displacement of Coup-TFII repressor from gamma-globin-promoter, indicating that the PKC-alpha-Erk1/2 MAPK pathway contributes to SCF induced the gamma-globin gene induction in adult erythropoiesis. Furthermore, consistent with this concept, SCF induced the gamma-globin gene induction attenuated by inhibition of PKC-alpha or Erk1/2 MAPK. Our data suggest that SCF stimulates the PKC/ROS/Erk1/2 MAPK signaling pathway, which regulates the downstream repressor COUP-TFII (by inhibiting serine/threonine phosphatase 2A activity) and the transcriptional activator NF-Ya (by inducing Ref-1), and that decreased COUP-TFII expression and increased NF-Ya expression induce gamma-globin reactivation in adult erythropoiesis. These observations provide insight into the molecular pathways that regulate gamma-globin augmentation during stress erythropoiesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Glia maturation factor-gamma modulation of signaling pathways in macrophages
-
批准号:8939812
-
项目类别:
-
资助金额:$32.92万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
Olfactomedin 4 down-regulates neutrophil killing of Gram-positive and Gram-negat
-
批准号:8557968
-
项目类别:
-
资助金额:$70.74万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
Recombinant erythroid Kruppel-like factor fused to GATA1 upregulates globin expr
-
批准号:8557970
-
项目类别:
-
资助金额:$70.74万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
Glia maturation factor-gamma negatively modulates TLR4 signaling in macrophages
-
批准号:8149534
-
项目类别:
-
资助金额:$69.25万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
Recombinant erythroid Kruppel-like factor fused to GATA1 upregulates globin expr
-
批准号:8149535
-
项目类别:
-
资助金额:$69.25万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
Glia maturation factor-gamma modulation of signaling pathways in macrophages
-
批准号:9157363
-
项目类别:
-
资助金额:$56.41万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
Olfactomedin 4 down-regulates neutrophil killing of Gram-positive and Gram-negat
-
批准号:8344821
-
项目类别:
-
资助金额:$83.2万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
Olfactomedin 4 Suppresses Prostate Cancer Cell Growth and Metastasis via Negativ
-
批准号:8557967
-
项目类别:
-
资助金额:$70.74万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
Olfactomedin 4 Suppresses Prostate Cancer Cell Growth and Metastasis via Negativ
-
批准号:8939810
-
项目类别:
-
资助金额:$32.92万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
Glia maturation factor-gamma modulation of signaling pathways in macrophages
-
批准号:9357228
-
项目类别:
-
资助金额:$58.81万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
Olfactomedin 4 is a key regulator of human neutrophil function
-
批准号:10012677
-
项目类别:
-
资助金额:$52.01万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
Olfactomedin 4 Suppresses Prostate Cancer Cell Growth and Metastasis via Negativ
-
批准号:10253822
-
项目类别:
-
资助金额:$40.45万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
Olfactomedin 4 is a key regulator of colon cancer progression
-
批准号:8939811
-
项目类别:
-
资助金额:$32.92万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
Glia maturation factor-gamma modulation of signaling pathways in macrophages
-
批准号:8344822
-
项目类别:
-
资助金额:$83.2万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
Olfactomedin 4 Suppresses Prostate Cancer Cell Growth and Metastasis via Negativ
-
批准号:8344820
-
项目类别:
-
资助金额:$83.2万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
Olfactomedin 4 down-regulates neutrophil killing of Gram-positive and Gram-negat
-
批准号:8746604
-
项目类别:
-
资助金额:$38.54万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
Glia maturation factor-gamma modulation of signaling pathways in macrophages
-
批准号:8746605
-
项目类别:
-
资助金额:$38.54万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
Olfactomedin 4 Suppresses Prostate Cancer Cell Growth and Metastasis via Negativ
-
批准号:10706165
-
项目类别:
-
资助金额:$59.52万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
Olfactomedin 4- a key regulator of human neutrophil function, role in small intestinal adenocarcinoma.
-
批准号:10253823
-
项目类别:
-
资助金额:$40.45万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
Olfactomedin 4 Suppresses Prostate Cancer Cell Growth and Metastasis via Negativ
-
批准号:10929107
-
项目类别:
-
资助金额:$64.05万
-
财政年份:--
-
负责人:GRIFFIN RODGERS
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: